Morgan Joseph Upgrades BioMarin (BMRN) to Buy, A Genzyme Deal Could Highlight Attractiveness
Tweet Send to a Friend
Morgan Joseph upgrades BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) from Hold to Buy with a $25 price target.
The firm ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
The firm ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
